The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia
©2024 American Association for Cancer Research..
Eradication of acute myeloid leukemia (AML) is therapeutically challenging; many patients succumb to AML despite initially responding to conventional treatments. Here, we showed that the imipridone ONC213 elicits potent antileukemia activity in a subset of AML cell lines and primary patient samples, particularly in leukemia stem cells, while producing negligible toxicity in normal hematopoietic cells. ONC213 suppressed mitochondrial respiration and elevated α-ketoglutarate by suppressing α-ketoglutarate dehydrogenase (αKGDH) activity. Deletion of OGDH, which encodes αKGDH, suppressed AML fitness and impaired oxidative phosphorylation, highlighting the key role for αKGDH inhibition in ONC213-induced death. ONC213 treatment induced a unique mitochondrial stress response and suppressed de novo protein synthesis in AML cells. Additionally, ONC213 reduced the translation of MCL1, which contributed to ONC213-induced apoptosis. Importantly, a patient-derived xenograft from a relapsed AML patient was sensitive to ONC213 in vivo. Collectively, these findings support further development of ONC213 for treating AML.
SIGNIFICANCE: In AML cells, ONC213 suppresses αKGDH, which induces a unique mitochondrial stress response, and reduces MCL1 to decrease oxidative phosphorylation and elicit potent antileukemia activity. See related commentary by Boët and Sarry, p. 950.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:84 |
|---|---|
| Enthalten in: |
Cancer research - 84(2024), 7 vom: 01. Apr., Seite 1084-1100 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Su, Yongwei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 03.04.2024 Date Revised 10.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1158/0008-5472.CAN-23-2659 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367565269 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367565269 | ||
| 003 | DE-627 | ||
| 005 | 20240410232430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-23-2659 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM367565269 | ||
| 035 | |a (NLM)38266099 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Su, Yongwei |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2024 American Association for Cancer Research. | ||
| 520 | |a Eradication of acute myeloid leukemia (AML) is therapeutically challenging; many patients succumb to AML despite initially responding to conventional treatments. Here, we showed that the imipridone ONC213 elicits potent antileukemia activity in a subset of AML cell lines and primary patient samples, particularly in leukemia stem cells, while producing negligible toxicity in normal hematopoietic cells. ONC213 suppressed mitochondrial respiration and elevated α-ketoglutarate by suppressing α-ketoglutarate dehydrogenase (αKGDH) activity. Deletion of OGDH, which encodes αKGDH, suppressed AML fitness and impaired oxidative phosphorylation, highlighting the key role for αKGDH inhibition in ONC213-induced death. ONC213 treatment induced a unique mitochondrial stress response and suppressed de novo protein synthesis in AML cells. Additionally, ONC213 reduced the translation of MCL1, which contributed to ONC213-induced apoptosis. Importantly, a patient-derived xenograft from a relapsed AML patient was sensitive to ONC213 in vivo. Collectively, these findings support further development of ONC213 for treating AML | ||
| 520 | |a SIGNIFICANCE: In AML cells, ONC213 suppresses αKGDH, which induces a unique mitochondrial stress response, and reduces MCL1 to decrease oxidative phosphorylation and elicit potent antileukemia activity. See related commentary by Boët and Sarry, p. 950 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Myeloid Cell Leukemia Sequence 1 Protein |2 NLM | |
| 700 | 1 | |a Carter, Jenna L |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Fukuda, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, John |e verfasserin |4 aut | |
| 700 | 1 | |a Edwards, Holly |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Schreiner, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Polin, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kushner, Juiwanna |e verfasserin |4 aut | |
| 700 | 1 | |a Dzinic, Sijana H |e verfasserin |4 aut | |
| 700 | 1 | |a Buck, Steven A |e verfasserin |4 aut | |
| 700 | 1 | |a Pruett-Miller, Shondra M |e verfasserin |4 aut | |
| 700 | 1 | |a Hege-Hurrish, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Camenzind |e verfasserin |4 aut | |
| 700 | 1 | |a Qiao, Xinan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shuangshuang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Guan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Joshua E |e verfasserin |4 aut | |
| 700 | 1 | |a Prabhu, Varun V |e verfasserin |4 aut | |
| 700 | 1 | |a Schimmer, Aaron D |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Dhananjay |e verfasserin |4 aut | |
| 700 | 1 | |a Kalhor-Monfared, Shiva |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Iain D G |e verfasserin |4 aut | |
| 700 | 1 | |a Marcellus, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Isaac, Methvin B |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Awar, Rima |e verfasserin |4 aut | |
| 700 | 1 | |a Taub, Jeffrey W |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Hai |e verfasserin |4 aut | |
| 700 | 1 | |a Schuetz, John D |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Yubin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 84(2024), 7 vom: 01. Apr., Seite 1084-1100 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:84 |g year:2024 |g number:7 |g day:01 |g month:04 |g pages:1084-1100 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-23-2659 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 84 |j 2024 |e 7 |b 01 |c 04 |h 1084-1100 | ||